Wutah dodolan YoY sajrone 12 wulan kepungkur: Biogen Idec (BIIB)

High risks of clinical failures and regulatory pressure create volatility, as demonstrated by the annual sales growth rate (trailing 12 months). The value of 2.10 shows the latest reading of this trend. This price action is supported by the market launch of Leqembi and Skyclarys, while high margins on key products and steady cash flow provide Biogen Inc. (BIIB) with the financial resilience to drive innovation.
Biogen Inc (BIIB) - rincian metrik lan laporan keuangan

This indicator captures the rolling annual business scaling rate, measuring operating revenue dynamics over the last twelve months to assess real market expansion. By analyzing this rolling 12-month YoY revenue growth chart, an investor can identify the cash flow volatility of Biogen Inc. (BIIB), driven by a reliance on aging products and uncertainty surrounding the outcomes of clinical trials for new neurological drugs.